Pelvic organ prolapse
Conditions
Interventions
The control group,SF:group SF received sufentanil PCIA
celecoxib group,CSF:received oral celecoxib on the basis of group SF
sacral plexus block combined with celecoxib group,SPBC:sacral plexus block (SPB) combined with celecoxib group
Sponsors
Hangzhou Women's Hospital
Eligibility
Sex/Gender
Female
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Age 50~80 years old; ? ASA class I~III, anesthesia evaluation without contraindications to peripheral nerve block anesthesia; ? Obtaining the patient's consent and signing the informed consent for anesthesia
Exclusion criteria
Exclusion criteria: ? BMI>30; ? severe cardiovascular disease, liver and kidney function abnormalities, metabolic diseases, central nervous system disease; ? peptic ulcer ? long-term opioid users; ? untreated patients with obstructive sleep apnea syndrome; ? history of allergy to known study medications; ? mental dysfunction; elderly people with Helmholtz's disease or Parkinson's disease; ? inability to complete the survey questionnaires, the subject of the test halfway (ix) Inability to complete the questionnaire and unauthorized discontinuation of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| morphine equivalent; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog pain score, VAS;Bromage; | — |
Countries
China
Contacts
Public ContactXiaoyun Dong
Hangzhou Women's Hospital
Outcome results
None listed